<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117453</url>
  </required_header>
  <id_info>
    <org_study_id>P120127</org_study_id>
    <secondary_id>2013-002531-15</secondary_id>
    <nct_id>NCT02117453</nct_id>
  </id_info>
  <brief_title>Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides</brief_title>
  <acronym>STATVAS</acronym>
  <official_title>Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether rosuvastatin could reduce the subclinical&#xD;
      markers of atherosclerosis and the incidence of major cardiovascular events in patients with&#xD;
      primary necrotizing vasculitides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies demonstrated the presence of subclinical atherosclerosis in patients with&#xD;
      ANCA-associated systemic necrotizing vasculitis. Since statins lower levels of inflammatory&#xD;
      proteins and cholesterol, we hypothesized that people with ANCA-associated systemic&#xD;
      necrotizing vasculitis but without indication for statin treatment according to&#xD;
      recommandations might benefit from statin treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2014</start_date>
  <completion_date type="Actual">November 7, 2019</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in mean carotid intima-media thickness for 6 predefined sites</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed with B-mode ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in mean carotid intima-media thickness for 6 predefined sites (distal common carotid arteries, carotid bulbs, internal carotid arteries), assessed with B-mode ultrasound</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed with B-mode ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in the number of plaques in three peripheral vessels (carotid and femoral arteries and abdominal aorta)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed with B-mode ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in serum biomarkers of subclinical atherosclerosis</measure>
    <time_frame>24 months</time_frame>
    <description>ultra-sensitive CRP, VCAM-1, P-selectin, thrombomodulin, circulating endothelial, platelet and leucocytes microparticles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major cardiovascular events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in vasculitis activity</measure>
    <time_frame>24 months</time_frame>
    <description>BVAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of vasculitis relapses</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in lipid profile (triglycerids, total, HDL and LDL cholesterol) compared to baseline value.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in endothelial function with brachial artery flow-mediated dilatation compared to baseline value</measure>
    <time_frame>24 months</time_frame>
    <description>endothelial function with brachial artery flow-mediated dilatation at months 6, 12 and 24 compared to baseline value, assessed with B-mode ultrasound in a subgroup of 66 patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>ANCA-associated Primary Necrotizing Vasculitides</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20 mg/day</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient &gt; 18 years. ANCA-associated vasculitis: granulomatosis with polyangiitis (GPA),&#xD;
        microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA,&#xD;
        Churg-Strauss syndrome).&#xD;
&#xD;
        Patients will fulfill the Chapel Hill Consensus Criteria and the American College of&#xD;
        Rheumatology criteria, in remission of vasculitis.&#xD;
&#xD;
        Patients in remission of vasculitis after induction therapy (for first flare or relapse),&#xD;
        including corticosteroids associated or not with immunosuppressive agents according to Good&#xD;
        Clinical Practice for the treatment of vasculitis, between 6 months and 10 years after the&#xD;
        beginning of induction therapy.&#xD;
&#xD;
        Patients with informed and signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Other systemic vasculitis. Secondary vasculitis (paraneoplastic or infectious). Patient&#xD;
        with active vasculitis after induction therapy, requiring salvage therapy.&#xD;
&#xD;
        Inability to sign informed consent. Inability to take the experimental treatment.&#xD;
        Hypersensitivity to rosuvastatin or to any of the excipients. Pregnancy. Chronic HCV, HBV&#xD;
        and/or HIV infection. Patient receiving other statin or other hypolipemic agent. Patient&#xD;
        requiring treatment with statin according to Afssaps recommandations published in 2005 as&#xD;
        primary or secondary prevention.&#xD;
&#xD;
        Subclinical atherosclerosis that confers a high cardiovascular risk before patient&#xD;
        randomization :&#xD;
&#xD;
          -  Carotid stenosis greater than 50% in diameter&#xD;
&#xD;
          -  Ectasia of the abdominal aorta&#xD;
&#xD;
          -  Intima-media thickening greater than 1.2 mm&#xD;
&#xD;
          -  Diffuse atherosclerosis lesions&#xD;
&#xD;
          -  Heterogeneous or hypoechoic prominent plaques greater than 2 mm Participation in&#xD;
             another interventional study within 3 months before inclusion. Sick patients will not&#xD;
             be excluded if they participate simultaneously in a strictlu observational study or a&#xD;
             study with only blood samplings.&#xD;
&#xD;
        Any medical or psycatric disease that could prevent from administrating drugs or from&#xD;
        following-up the patient according the to protocol, and/or that would expose the patient to&#xD;
        an important number of side effects, according to the principal investigator.&#xD;
&#xD;
        Non affiliation to a social security system or any social protection system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANCA vasculitis</keyword>
  <keyword>Statin</keyword>
  <keyword>Subclinical markers of atherosclerosis</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Stroke</keyword>
  <keyword>Arterial revascularization</keyword>
  <keyword>Unstable angina</keyword>
  <keyword>Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

